EUHASS: The European Haemophilia Safety Surveillance system

被引：77

作者：

Makris, M. ^{[1
]}

Calizzani, G.

Fischer, K. ^{[2
]}

Gilman, E. A. ^{[1
]}

Hay, C. R. M. ^{[3
]}

Lassila, R. ^{[4
]}

Lambert, T. ^{[5
]}

Ludlam, C. A.

Mannucci, P. M. ^{[6
]}

机构：

[1] Univ Sheffield, Sheffield S10 2TN, S Yorkshire, England

[2] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Dept Hematol, Van Creveldklin, Utrecht, Netherlands

[3] Manchester Royal Infirm, Manchester, Lancs, England

[4] Univ Helsinki, Cent Hosp, FIN-00014 Helsinki, Finland

[5] Paris AP HP Haemophilia Treatment Ctr, Paris, France

[6] Univ Milan, I-20122 Milan, Italy

来源：

THROMBOSIS RESEARCH | 2011年 / 127卷

关键词：

Haemophilia; Adverse events; Inhibitor; Thrombosis; BLEEDING DISORDERS; PHARMACOVIGILANCE;

D O I：

10.1016/S0049-3848(10)70150-X

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Pharmacovigilance is an essential element of any drug treatment and considering the history of adverse events due to products used to treat inherited bleeding disorders, it should be an integral component of modern haemophilia treatment. Because inherited bleeding disorders and adverse events are rare, a multicentre, preferably multinational, adverse event reporting scheme for all clotting factor products is required. EUHASS is a European, prospective, multicentre adverse event reporting scheme in the field of inherited bleeding disorders. (C) 2010 Elsevier Ltd. All rights reserved.

引用

页码：S22 / S25

页数：4

共 6 条

[1] Current challenges of pharmacovigilance in bleeding disorders: converting the burden to benefit [J].